Device Trial Radar · NCT03988244
HeartLight X3 Endoscopic Ablation System With Excalibur Balloon for Treatment of Symptomatic Persistent AF
Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Feb 26, 2019
Primary completion
Apr 30, 2019
Study completion Apr 3, 2020
Sponsor
- Lead sponsor
- CardioFocusNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 17, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to demonstrate the improved ablation and procedure times of the HeartLight X3 compared to the original HeartLight catheter in the treatment of persistent atrial fibrillation.
Conditions
- Atrial Fibrillation
Interventions
HeartLight X3Device
Pulmonary vein isolation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ablation timeTime frame: Acute - at the end of the index procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nemocnice Na Homolce
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.